Literature DB >> 26368648

Transmucosal Immediate-Release Fentanyl for Breakthrough Cancer Pain: Opportunities and Challenges for Use in Palliative Care.

Andrew Chang, Eric J Roeland, Rabia S Atayee, Carolyn Revta, Joseph D Ma.   

Abstract

Opioids are used to treat breakthrough cancer pain (BTCP) and can be classified by relative duration and onset of action. Regulatory approvals of numerous transmucosal immediate-release fentanyl (TIRF) formulations provide alternative options to palliative care-trained providers in the management of BTCP. TIRFs have been formulated as a sublingual tablet, sublingual spray, intranasal spray, pectin-based nasal spray, buccal tablet, and buccal soluble film. Differences exist between TIRFs regarding formulation design and dosing to treat BTCP. Opportunities for use include palliation of BTCP in head and neck cancer and/or radiation-induced mucositis. The purpose of this review is to discuss TIRF formulation and dosing, pharmacokinetics, clinical efficacy, patient acceptability, and safety/tolerability. In addition, barriers to TIRF utilization will be discussed.

Entities:  

Keywords:  fentanyl; opioid; pain management; palliative care; rapid onset

Mesh：

Substances：

Year:  2015        PMID： 26368648     DOI： 10.3109/15360288.2015.1063560

Source DB:  PubMed          Journal:  J Pain Palliat Care Pharmacother        ISSN： 1536-0288


  9 in total

1.  A dose titration study of fentanyl buccal soluble film for breakthrough cancer pain in Taiwan.

Authors:  Tzeon-Jye Chiou; Ta-Chung Chao; Tsu-Yi Chao; Jen-Seng Huang; Yi-Fang Chang; Cheng-Hsu Wang
Journal:  Cancer Rep (Hoboken)       Date:  2019-04-23

Review 2.  Rapid-Onset Opioids for Management of Breakthrough Cancer Pain: Considerations for Daily Practice.

Authors:  Paolo Bossi; Yolanda Escobar; Federico Pea
Journal:  Front Pain Res (Lausanne)       Date:  2022-05-26

Review 3.  Fentanyl Buccal Soluble Film: A Review in Breakthrough Cancer Pain.

Authors:  Karly P Garnock-Jones
Journal:  Clin Drug Investig       Date:  2016-05       Impact factor: 2.859

4.  Fentanyl buccal tablet for breakthrough cancer pain in clinical practice: results of the non-interventional prospective study ErkentNIS.

Authors:  Eva Katharina Masel; Robert Landthaler; Margit Gneist; Herbert Hans Watzke
Journal:  Support Care Cancer       Date:  2017-08-28       Impact factor: 3.603

5.  Cost-effectiveness analysis of oral fentanyl formulations for breakthrough cancer pain treatment.

Authors:  Paolo Angelo Cortesi; Lucia Sara D'Angiolella; Renato Vellucci; Massimo Allegri; Giuseppe Casale; Carlo Favaretti; Flavia Kheiraoui; Giancarlo Cesana; Lorenzo Giovanni Mantovani
Journal:  PLoS One       Date:  2017-06-27       Impact factor: 3.240

6.  Fentanyl nasal spray in a patient with end-stage COPD and severe chronic breathlessness.

Authors:  Daisy J A Janssen; Marieke H J van den Beuken-van Everdingen; Cornelia A Verberkt; Jacques P H M Creemers; Emiel F M Wouters
Journal:  Breathe (Sheff)       Date:  2019-09

Review 7.  Transmucosal drug administration as an alternative route in palliative and end-of-life care during the COVID-19 pandemic.

Authors:  Jenny K W Lam; Chucky C K Cheung; Michael Y T Chow; Emily Harrop; Susie Lapwood; Stephen I G Barclay; Ian C K Wong
Journal:  Adv Drug Deliv Rev       Date:  2020-11-01       Impact factor: 15.470

8.  The use of fentanyl in pain management in head and neck cancer patients: a narrative review.

Authors:  Raffaele Giusti; Paolo Bossi; Marco Mazzotta; Marco Filetti; Daniela Iacono; Paolo Marchetti
Journal:  Br J Pain       Date:  2017-10-10

9.  Proportional dose of rapid-onset opioid in breakthrough cancer pain management: An open-label, multicenter study.

Authors:  Tsung-Yu Yen; Jeng-Fong Chiou; Wei-Yong Chiang; Wen-Hao Su; Ming-Yuan Huang; Ming-Hung Hu; Shen-Chi Wu; Yuen-Liang Lai
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.